CN103732244A - 通过施用重组vwf治疗凝血疾病 - Google Patents

通过施用重组vwf治疗凝血疾病 Download PDF

Info

Publication number
CN103732244A
CN103732244A CN201280038870.7A CN201280038870A CN103732244A CN 103732244 A CN103732244 A CN 103732244A CN 201280038870 A CN201280038870 A CN 201280038870A CN 103732244 A CN103732244 A CN 103732244A
Authority
CN
China
Prior art keywords
var
rvwf
vwf
fviii
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280038870.7A
Other languages
English (en)
Chinese (zh)
Inventor
F·沙伊芙林格
P·图雷切克
B·埃文斯汀
Y·W·王
M·T·休特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hundred Deep Co
Hundred Deep LLC
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Priority to CN201611071108.5A priority Critical patent/CN107412743B/zh
Priority to CN201810079423.5A priority patent/CN108210889A/zh
Publication of CN103732244A publication Critical patent/CN103732244A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN201280038870.7A 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病 Pending CN103732244A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201611071108.5A CN107412743B (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病
CN201810079423.5A CN108210889A (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201611071108.5A Division CN107412743B (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病
CN201810079423.5A Division CN108210889A (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病

Publications (1)

Publication Number Publication Date
CN103732244A true CN103732244A (zh) 2014-04-16

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201280038870.7A Pending CN103732244A (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病
CN201611071108.5A Active CN107412743B (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病
CN201810079423.5A Pending CN108210889A (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201611071108.5A Active CN107412743B (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病
CN201810079423.5A Pending CN108210889A (zh) 2011-06-10 2012-06-11 通过施用重组vwf治疗凝血疾病

Country Status (24)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN103732244A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL2717905T3 (enExample)
PT (3) PT3412305T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111436193A (zh) * 2017-07-07 2020-07-21 百深公司 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血
CN111565741A (zh) * 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP4343774A3 (en) 2016-04-15 2024-06-05 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
SG11202006902QA (en) 2018-02-06 2020-08-28 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3768697A1 (en) * 2018-03-21 2021-01-27 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
MX2021009114A (es) * 2019-02-01 2021-10-13 Takeda Pharmaceuticals Co Métodos de tratamiento profiláctico que usan factor de von willebrand recombinante (rvwf).
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854403A (en) * 1994-10-04 1998-12-29 Immuno Aktiengesellschaft Method for isolation of highly pure von Willebrand Factor
US20100099603A1 (en) * 2008-10-21 2010-04-22 Baxter International Inc. Lyophilized recombinant vwf formulations
WO2012006591A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
DK1974014T3 (en) 2006-01-04 2017-06-19 Baxalta Inc OLIGOPEPTID-FREE CELL CULTURE MEDIA
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
EP2222329A1 (en) 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
MX2010007150A (es) * 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
WO2011017414A2 (en) * 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854403A (en) * 1994-10-04 1998-12-29 Immuno Aktiengesellschaft Method for isolation of highly pure von Willebrand Factor
US20100099603A1 (en) * 2008-10-21 2010-04-22 Baxter International Inc. Lyophilized recombinant vwf formulations
WO2012006591A1 (en) * 2010-07-08 2012-01-12 Baxter International Inc. METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TURECEK PL ET AL.: "structure and function of a recombinant von willebrand factor drug candidate", 《SEMINARS IN THROMBOSIS AND HEMOSTASIS》, vol. 36, no. 5, 1 July 2010 (2010-07-01), pages 510 - 522, XP009162279 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111436193A (zh) * 2017-07-07 2020-07-21 百深公司 通过施用重组vwf来治疗患有严重冯维勒布兰德病的患者中的胃肠道出血
CN111565741A (zh) * 2017-07-07 2020-08-21 百深公司 通过施用重组vwf来治疗经历择期手术的患有严重冯维勒布兰德病的患者

Also Published As

Publication number Publication date
DK2717905T3 (en) 2018-07-02
AU2020200026A1 (en) 2020-01-30
EP3858375A1 (en) 2021-08-04
CA2838845C (en) 2019-08-06
US20120316116A1 (en) 2012-12-13
AU2016202299B2 (en) 2017-07-20
MX2013014543A (es) 2014-06-11
LT2717905T (lt) 2018-10-10
SI2717905T1 (sl) 2018-09-28
BR112013031795A2 (pt) 2016-12-20
DK3858375T3 (da) 2024-04-15
KR20200091476A (ko) 2020-07-30
EP3858375B1 (en) 2024-03-20
US9272021B2 (en) 2016-03-01
JP6347468B2 (ja) 2018-06-27
JP6527114B2 (ja) 2019-06-05
AU2012267458A1 (en) 2014-01-09
CA2838845A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
RU2019103386A3 (enExample) 2022-01-24
JP2014516088A (ja) 2014-07-07
CN108210889A (zh) 2018-06-29
ES2860450T3 (es) 2021-10-05
NZ618790A (en) 2015-07-31
KR102319868B1 (ko) 2021-11-01
KR20190041032A (ko) 2019-04-19
RU2680402C2 (ru) 2019-02-21
ES2682249T3 (es) 2018-09-19
PL3412305T3 (pl) 2021-05-31
HRP20180962T1 (hr) 2018-10-19
EP3412305B1 (en) 2021-01-06
HK1257436A1 (zh) 2019-10-18
MX2020000083A (es) 2020-08-06
ES2976169T3 (es) 2024-07-24
EP3412305A1 (en) 2018-12-12
RU2014100107A (ru) 2015-07-20
US20250387455A1 (en) 2025-12-25
AU2016202299A1 (en) 2016-05-05
AU2022201518B2 (en) 2025-07-03
EP2717905A1 (en) 2014-04-16
AR086904A1 (es) 2014-01-29
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
FI3858375T3 (fi) 2024-04-17
AU2022201518A1 (en) 2022-03-24
PT2717905T (pt) 2018-07-02
TR201808823T4 (tr) 2018-07-23
DK3412305T3 (da) 2021-03-01
HUE039317T2 (hu) 2018-12-28
JP2017019788A (ja) 2017-01-26
PL2717905T3 (pl) 2018-10-31
WO2012171031A1 (en) 2012-12-13
MX350582B (es) 2017-09-11
EP2717905B1 (en) 2018-05-23
PT3858375T (pt) 2024-04-18
RU2019103386A (ru) 2020-08-07
RU2628537C2 (ru) 2017-08-18
CN107412743A (zh) 2017-12-01
SG10202002591QA (en) 2020-05-28
RU2017102679A3 (enExample) 2018-12-19
AU2017206235A1 (en) 2017-08-03
US20160184403A1 (en) 2016-06-30
CN107412743B (zh) 2021-07-02
SG10201604684WA (en) 2016-07-28
RU2017102679A (ru) 2018-12-19
KR20140039285A (ko) 2014-04-01
AU2017206235B2 (en) 2019-10-17
PT3412305T (pt) 2021-01-29

Similar Documents

Publication Publication Date Title
US20250387455A1 (en) Treatment of coagulation disease by administration of recombinant vwf
US12016904B2 (en) Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
RU2787855C2 (ru) Лечение нарушений свертываемости крови путем введения рекомбинантного фактора виллебранда
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf
US20230398188A1 (en) Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160811

Address after: Aupu, Switzerland

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Illinois State

Applicant before: Baxter International Inc.

Applicant before: Bakst Helth Co., Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: Zug City

Applicant after: Hundred deep limited liability company

Applicant after: Hundred deep company

Address before: Aupu, Switzerland

Applicant before: Hundred deep limited liability company

Applicant before: Hundred deep company

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20140416